Russell Investments Group Ltd. grew its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 41.4% during the third quarter, HoldingsChannel reports. The firm owned 170,089 shares of the biotechnology company’s stock after buying an additional 49,785 shares during the period. Russell Investments Group Ltd.’s holdings in Ligand Pharmaceuticals were worth $53,131,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the company. Maryland State Retirement & Pension System lifted its position in shares of Ligand Pharmaceuticals by 51.7% during the third quarter. Maryland State Retirement & Pension System now owns 4,433 shares of the biotechnology company’s stock worth $1,385,000 after purchasing an additional 1,510 shares in the last quarter. Jacobi Capital Management LLC purchased a new position in shares of Ligand Pharmaceuticals in the third quarter valued at $31,000. Jefferies Financial Group Inc. acquired a new stake in Ligand Pharmaceuticals during the 3rd quarter valued at $1,335,000. Illinois Municipal Retirement Fund grew its holdings in Ligand Pharmaceuticals by 4.7% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 10,144 shares of the biotechnology company’s stock valued at $3,169,000 after purchasing an additional 453 shares in the last quarter. Finally, Lido Advisors LLC grew its holdings in Ligand Pharmaceuticals by 11.6% during the 3rd quarter. Lido Advisors LLC now owns 2,809 shares of the biotechnology company’s stock valued at $877,000 after purchasing an additional 292 shares in the last quarter. Hedge funds and other institutional investors own 91.28% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on LGND shares. Weiss Ratings downgraded shares of Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research note on Monday, November 2nd. Royal Bank Of Canada upped their price objective on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Oppenheimer reissued an “outperform” rating and issued a $326.00 price objective (up from $285.00) on shares of Ligand Pharmaceuticals in a research report on Monday, August 3rd. Citigroup raised their target price on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $358.00 target price on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $355.38.
Insider Activity at Ligand Pharmaceuticals
In related news, Director Martine Zimmermann sold 1,200 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $285.00, for a total value of $342,000.00. Following the sale, the director directly owned 3,897 shares of the company’s stock, valued at $1,110,645. This represents a 23.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $313.22, for a total transaction of $1,566,100.00. Following the transaction, the insider owned 31,854 shares in the company, valued at $9,977,309.88. This trade represents a 13.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,593 shares of company stock valued at $6,585,447 over the last ninety days. Corporate insiders own 5.60% of the company’s stock.
Ligand Pharmaceuticals Stock Performance
Shares of LGND opened at $308.79 on Monday. The business’s 50 day moving average is $301.71 and its two-hundred day moving average is $258.02. Ligand Pharmaceuticals Incorporated has a 52-week low of $175.89 and a 52-week high of $326.63. The firm has a market cap of $6.18 billion, a price-to-earnings ratio of 137.85, a PEG ratio of 5.39 and a beta of 1.16. The company has a quick ratio of 1.19, a current ratio of 1.22 and a debt-to-equity ratio of 0.71.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last released its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 EPS for the quarter, beating the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. The company had revenue of $78.75 million during the quarter, compared to analysts’ expectations of $77.00 million. During the same period in the prior year, the business posted $3.09 EPS. The business’s revenue was down 31.8% on a year-over-year basis. Analysts forecast that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current fiscal year.
Ligand Pharmaceuticals Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Featured Articles
- Five stocks we like better than Ligand Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report).
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
